Company Profile

"Meiji Seika Co., Ltd. Kamonomiya Plant" established

Meiji Seika Co., Ltd. Research Division established

The site was renovated from a food processing plant into a pharmaceutical manufacturing facility and initiated the production of pharmaceuticals under the name "Meiji Seika Co., Ltd. Odawara Plant."

Commencement of production for 'Arbekacin Sulfate', the first antibiotic in Japan specifically developed to treat MRSA infection.

Accreditation of ISO14001 certification

Commencement of manufacturing 'Talaporfin Sodium', a photosensitizer for Photodynamic Therapy (PDT).

The Yodogawa Plant was integrated with the Odawara Plant, consolidating the main oral formulations into the New Solid Dosage Form Manufacturing Building (Building No. 5).

Started production of oral carbapenem antibiotic 'Tebipenem Pivoxil'

The Meiji Group's business restructuring led to the establishment of the "Meiji Seika Pharma Co., Ltd. Odawara Plant."

Completion of the Cephalosporin Antibiotic Manufacturing Building (Building No. 2) and the Carbapenem Antibiotic Manufacturing Building (Building No. 7).

Establishment of "Meiji Seika Pharmatech Co., Ltd.," a pharmaceutical formulation and manufacturing company.

"Meiji Seika Pharmatech Co., Ltd." began operations.